Company intelligence / Profile preview
Revolution Medicines
Redwood City, California, USArevmed.com ↗
- Ownership
- Public · RVMD
- Employees
- ~188
- Development stage
- Phase 1
01
Overview
Revolution Medicines’ lead asset RMC‑6236 has advanced to a global Phase 3 trial for metastatic pancreatic ductal adenocarcinoma. In earlier studies, the drug showed encouraging progression-free survival—8.1 months median PFS in second-line patients with KRAS G12X mutations versus historical benchmarks of ~2–3.5 months for chemotherapy. The company’s pipeline includes several other clinical and preclinical mutant-selective RAS inhibitors targeting various solid tumors driven by different KRAS mutations
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
Former partnership with Sanofi on SHP2 program (terminated Dec 2022)Collaboration agreement with Aethon Therapeutics to create therapies for RAS-addicted cancers signed April 2024
04
Financials
- Market cap
- $38.1B
- Total revenue
- $0
- Enterprise value
- $35.1B
Beyond the preview
Go deeper on Revolution Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revolution Medicines.